Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: 20 years of experience from a specialist centre
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf338 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Sophie E L Bashall und 6 weiteren Autor:innen. Beteiligte Einrichtung: St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Skin Neoplasms, Lymphoproliferative Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-TLPD) is a rare subtype of indolent lymphoproliferative disease. The treatment, investigations and follow-up protocol are being re-evaluated.
Objectives
To use our service evaluation to understand the presentation, response rate, relapse rate, treatment variation, progression-free (PFS) and overall survival (OS) of our cohort.
Methods
We identified 86 patients with PCSM-TLPD from our skin tumour unit database who were diagnosed by the specialist multidisciplinary team at our centre between 2005 and 2024. As well as demographics and clinical features, OS, PFS, response to treatment and risk factors for relapse were investigated.
Results
Eighty-six patients [mean (SD) age 54.9 (14.1) years; median 56 years (range 17–87)] were included. The majority of PCSM-TLPD lesions presented as solitary nodules (n = 75) on the head and neck (n = 51). Eighty-one patients underwent imaging (positron emission tomography, n = 44; computed tomography of the thorax, abdomen and pelvis, n = 37), with no evidence of nodal or systemic involvement in 100% of cases. Forty-seven patients had a diagnostic biopsy that resulted in spontaneous resolution for 16 patients. Thirty-one patients had a residual lesion and were treated with topical steroids (n = 20) or radiotherapy (n = 11). Thirty-nine patients had a complete excision, followed by monitoring alone for 33 patients. Six had radiotherapy after excision. All patients achieved complete remission. Patients initially presenting with multiple lesions (n = 11) were more likely to relapse [7 of 11 with multiple (64%) vs. 3 of 75 (4%) with solitary lesions] (P < 0.001). Three patients died from unrelated illnesses during follow-up. The median duration of follow-up was 3.1 years (interquartile range 1.2–4.9). The median PFS was not reached due to insufficient events. The overall relapse rate was 12% following initial monitoring or treatment. To date, disease-specific survival is 100%.
Conclusions
PCSM-TLPD carries an excellent prognosis, especially for those presenting with a solitary lesion. There was no disease-related death in our patients up to 20 years after presentation. Staging scans confirm no systemic disease and may no longer be required for these patients. Patients can be monitored or treated with low dose radiotherapy (8 Gy in two fractions) if they do not respond to topical steroids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
ORCID-Profile: Sophie E L Bashall, Bjorn R Thomas, Van Sim, Mary Wain
Zitieren
APA
Bashall, S. E. L., Thomas, B. R., Sim, V., Wain, M., Child, F., Whittaker, S., & Morris, S. (2025). Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: 20 years of experience from a specialist centre. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf338
Vancouver
Bashall SEL, Thomas BR, Sim V, Wain M, Child F, Whittaker S, et al. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: 20 years of experience from a specialist centre. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf338
BibTeX
@article{Bashall2025,
author = {Bashall, Sophie E L and Thomas, Bjorn R and Sim, Van and Wain, Mary and Child, Fiona and Whittaker, Sean and Morris, Stephen},
title = {Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: 20 years of experience from a specialist centre},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf338}
}
EUVIMED